We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), in connection with the proposed acquisition of the Company via a tender offer by funds managed by an affiliate of EW Healthcare Partners.  Under the terms of the merger agreement, the Company’s shareholders will receive $10.00 in cash for each share of TherapeuticsMD common stock owned.  The transaction is valued at approximately $177 million.

Weiss Law is investigating whether (i) TherapeuticsMD’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $10.00 per-share tender offer consideration adequately compensates TherapeuticsMD’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.